Imunon Financial Statements From 2010 to 2026

IMNN Stock

USD 3.69 0.17 4.40%

Imunon's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Imunon's valuation are provided below:

Gross Profit

2.7 M

Market Capitalization

13.1 M

Enterprise Value Revenue

4.0043

Revenue

125 K

Earnings Share

(12.53)

We have found one hundred twenty available fundamental trends for Imunon Inc, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to confirm Imunon's regular fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 10th of January 2026, Market Cap is likely to drop to about 7.7 M. In addition to that, Enterprise Value is likely to drop to about 3.1 M

Imunon Total Revenue

0.0

Check Imunon financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Imunon's main balance sheet or income statement drivers, such as Depreciation And Amortization of 867.1 K, Interest Expense of 0.0 or Selling General Administrative of 6.3 M, as well as many indicators such as Price To Sales Ratio of 24.23, Dividend Yield of 0.0 or PTB Ratio of 2.8. Imunon financial statements analysis is a perfect complement when working with Imunon Valuation or Volatility modules.

Build AI portfolio with Imunon Stock

Check out the analysis of Imunon Correlation against competitors.

Imunon Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

10.6 M

11.2 M

35.4 M

Pretty Stable

Short and Long Term Debt Total

1.2 M

1.3 M

5 M

Pretty Stable

Other Current Liabilities

2.1 M

3.5 M

2.5 M

Slightly volatile

Total Current Liabilities

5.4 M

5.5 M

6.6 M

Pretty Stable

Total Stockholder Equity

4.6 M

4.9 M

19.4 M

Pretty Stable

Property Plant And Equipment Net

2 M

1.9 M

1.1 M

Slightly volatile

Accounts Payable

2.2 M

1.5 M

2.6 M

Very volatile

Cash

7.7 M

6.8 M

10.1 M

Very volatile

Non Current Assets Total

1.9 M

2 M

12.9 M

Pretty Stable

Non Currrent Assets Other

42.8 K

45 K

872 K

Pretty Stable

Cash And Short Term Investments

6.4 M

6.8 M

21.1 M

Pretty Stable

Net Receivables

110.2 K

116 K

118.5 K

Slightly volatile

Common Stock Shares Outstanding

1.1 M

1 M

274.6 K

Slightly volatile

Liabilities And Stockholders Equity

10.6 M

11.2 M

35.4 M

Pretty Stable

Non Current Liabilities Total

750.5 K

790 K

9.4 M

Slightly volatile

Inventory

870.9 K

1.6 M

1.1 M

Slightly volatile

Other Current Assets

2.6 M

2.5 M

1.3 M

Slightly volatile

Other Stockholder Equity

496.2 M

472.5 M

296.3 M

Slightly volatile

Total Liabilities

6 M

6.3 M

16 M

Pretty Stable

Total Current Assets

8.7 M

9.2 M

22.5 M

Pretty Stable

Short Term Debt

494.2 K

520.2 K

1.4 M

Pretty Stable

Intangible Assets

16.1 M

15.4 M

14.9 M

Pretty Stable

Common Stock

124 K

130.5 K

157.4 K

Slightly volatile

Other Liabilities

6 M

4.9 M

8.3 M

Slightly volatile

Other Assets

0.86

0.9

1.2 M

Pretty Stable

Long Term Debt

5.1 M

4.1 M

7.4 M

Slightly volatile

Net Invested Capital

3.6 M

3.8 M

26 M

Slightly volatile

Capital Stock

137 K

130.5 K

174.9 K

Slightly volatile

Non Current Liabilities Other

5.4 M

4.9 M

7.4 M

Slightly volatile

Net Working Capital

2.8 M

2.9 M

18.3 M

Slightly volatile

Property Plant Equipment

1.2 M

809.8 K

593.1 K

Slightly volatile

Capital Lease Obligations

860 K

1 M

1.3 M

Slightly volatile

Property Plant And Equipment Gross

2.5 M

2.6 M

4 M

Slightly volatile

Short and Long Term Debt

1.2 M

1.3 M

1.6 M

Slightly volatile

Imunon Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

867.1 K

825.8 K

562.6 K

Slightly volatile

Selling General Administrative

6.3 M

8.6 M

7.6 M

Slightly volatile

Other Operating Expenses

17.7 M

22 M

20 M

Pretty Stable

Research Development

10.8 M

13.4 M

12.2 M

Very volatile

Cost Of Revenue

784.5 K

825.8 K

7.7 M

Slightly volatile

Total Operating Expenses

17.1 M

22 M

19.9 M

Pretty Stable

Selling And Marketing Expenses

11.8 B

11.2 B

9.4 B

Slightly volatile

Interest Income

473 K

517.8 K

391.5 K

Slightly volatile

Reconciled Depreciation

749.6 K

825.8 K

541.2 K

Slightly volatile

Imunon Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Begin Period Cash Flow

7.7 M

6.7 M

10.5 M

Pretty Stable

Depreciation

867.1 K

825.8 K

562.6 K

Slightly volatile

Capital Expenditures

32.3 K

34 K

221.8 K

Slightly volatile

End Period Cash Flow

8.1 M

6.8 M

10.8 M

Very volatile

Stock Based Compensation

521.4 K

548.8 K

1.7 M

Very volatile

Issuance Of Capital Stock

20.7 M

10.4 M

10 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

24.23

25.51

67.8826

Slightly volatile

PTB Ratio

2.8

2.67

3.2674

Slightly volatile

Days Sales Outstanding

177

108

126

Slightly volatile

Book Value Per Share

5.26

5.53

5.5 K

Slightly volatile

Average Payables

1.7 M

3.2 M

2.9 M

Slightly volatile

Stock Based Compensation To Revenue

3.19

4.81

4.0609

Slightly volatile

Capex To Depreciation

0.0449

0.0473

0.6449

Slightly volatile

PB Ratio

2.8

2.67

3.2674

Slightly volatile

Inventory Turnover

2.23

2.12

2.2102

Slightly volatile

Days Of Inventory On Hand

169

178

238

Slightly volatile

Payables Turnover

0.47

0.5

0.5312

Pretty Stable

Sales General And Administrative To Revenue

12.46

24.64

16.4093

Slightly volatile

Average Inventory

1.2 M

1.3 M

Slightly volatile

Research And Ddevelopement To Revenue

25.64

26.99

22.3614

Slightly volatile

Capex To Revenue

0.59

0.62

0.4044

Slightly volatile

Cash Per Share

7.27

7.65

2.8 K

Slightly volatile

Days Payables Outstanding

1.3 K

760

728

Pretty Stable

Income Quality

0.59

0.91

0.8571

Pretty Stable

Intangibles To Total Assets

0.15

0.16

0.2966

Very volatile

Current Ratio

1.83

1.92

3.4568

Pretty Stable

Receivables Turnover

4.24

4.46

13.4498

Pretty Stable

Shareholders Equity Per Share

5.26

5.53

5.5 K

Slightly volatile

Debt To Equity

0.25

0.24

0.2963

Very volatile

Capex Per Share

0.0366

0.0385

46.5449

Slightly volatile

Average Receivables

11.7 K

12.3 K

62.5 K

Slightly volatile

Revenue Per Share

1.0

1.05

132

Slightly volatile

Interest Debt Per Share

1.41

1.48

1.2 K

Slightly volatile

Debt To Assets

0.13

0.1172

0.1404

Very volatile

Graham Number

143.5 K

161.4 K

176.2 K

Slightly volatile

Operating Cycle

103

108

212

Slightly volatile

Price Book Value Ratio

2.8

2.67

3.2674

Slightly volatile

Days Of Payables Outstanding

1.3 K

760

728

Pretty Stable

Ebt Per Ebit

0.84

0.88

1.0502

Pretty Stable

Company Equity Multiplier

1.1

2.06

1.9884

Very volatile

Long Term Debt To Capitalization

0.25

0.16

0.1858

Pretty Stable

Total Debt To Capitalization

0.096

0.19

0.2099

Very volatile

Debt Equity Ratio

0.25

0.24

0.2963

Very volatile

Quick Ratio

1.83

1.92

3.445

Pretty Stable

Cash Ratio

1.34

1.41

1.5582

Pretty Stable

Days Of Inventory Outstanding

169

178

238

Slightly volatile

Days Of Sales Outstanding

177

108

126

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

1.12

1.15

1.0278

Slightly volatile

Price To Book Ratio

2.8

2.67

3.2674

Slightly volatile

Fixed Asset Turnover

0.78

0.82

1.0851

Slightly volatile

Debt Ratio

0.13

0.1172

0.1404

Very volatile

Price Sales Ratio

24.23

25.51

67.8826

Slightly volatile

Asset Turnover

0.0124

0.0131

0.0141

Slightly volatile

Gross Profit Margin

0.35

0.37

0.3854

Slightly volatile

Price Fair Value

2.8

2.67

3.2674

Slightly volatile

Imunon Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

7.7 M

8.1 M

43.1 M

Slightly volatile

Imunon Fundamental Market Drivers

Imunon Upcoming Events

	4th of April 2024 Upcoming Quarterly Report	View
	9th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	4th of April 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Imunon Financial Statements

Imunon investors utilize fundamental indicators, such as revenue or net income, to predict how Imunon Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	-4.3 M	-4.1 M
Cost Of Revenue	825.8 K	784.5 K
Stock Based Compensation To Revenue	4.81	3.19
Sales General And Administrative To Revenue	24.64	12.46
Research And Ddevelopement To Revenue	26.99	25.64
Capex To Revenue	0.62	0.59
Revenue Per Share	1.05	1.00
Ebit Per Revenue	(44.86)	(47.10)

Pair Trading with Imunon

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Imunon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Imunon will appreciate offsetting losses from the drop in the long position's value.

Moving together with Imunon Stock

0.81

LIPO

Lipella Pharmaceuticals

Pair Corr

Moving against Imunon Stock

0.87	DD	Dupont De Nemours	Pair Corr
0.81	AMGN	Amgen Inc	Pair Corr
0.78	ATI	Allegheny Technologies	Pair Corr
0.77	CSCO	Cisco Systems Sell-off Trend	Pair Corr
0.77	TRV	The Travelers Companies	Pair Corr

The ability to find closely correlated positions to Imunon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Imunon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Imunon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Imunon Inc to buy it.

The correlation of Imunon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Imunon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Imunon Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Imunon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Imunon Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Imunon's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Imunon Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Imunon Inc Stock:

How To Invest In Imunon

Details

Is Imunon Stock a good investment?

Details

What is Imunon's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Imunon Correlation against competitors.

You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(12.53)

Revenue Per Share

0.014

Return On Assets

(0.78)

Return On Equity

(2.33)

The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Imunon Financial Statements From 2010 to 2026

Imunon Total Revenue

0.0

Imunon Balance Sheet

Imunon Income Statement

Imunon Cash Flow Statement

Financial Ratios

Imunon Valuation Data

Imunon Fundamental Market Drivers

Imunon Upcoming Events

About Imunon Financial Statements

Pair Trading with Imunon

Moving together with Imunon Stock

Moving against Imunon Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY